<DOC>
	<DOCNO>NCT01282047</DOCNO>
	<brief_summary>Lenakap : This multicenter , non randomize ( single arm ) , open , phase II study aim evaluate efficacy Lenalidomide HIV-associated kaposi disease . Patients follow 48 week . Measurement primary endpoint 24 week .</brief_summary>
	<brief_title>Lenalidomide Kaposi Disease Associated With HIV Infection</brief_title>
	<detailed_description>Lenakap : This multicenter , non randomize ( single arm ) , open , phase II study aim evaluate efficacy Lenalidomide HIV-associated kaposi disease . Patients follow 48 week . Measurement primary endpoint 24 week . The observation period 48 week . The main criterion evaluate 24 week Inclusion period : 72 week setting-up meeting.Lenalidomide stop case progression patient consider drop-out trial , take account final analysis . Two-steps procedure : 14 evaluable patient first step ; one response treatment observe , patient include 25 evaluable patient .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Xeroderma Pigmentosum</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Men non childbearing ( negative serum Human Chorionic GonadotropinhCG ) non breastfeed woman practice adequate birth control , maintain 4 week stop lenalidomide Age 18 year 75 year Able willing give write informed consent Serologic documentation HIV infection approve test , undetectable HIV viral load ( 50 copies/mL ) independently CD4 cell count Biopsy proven symptomatic Kaposi sarcoma least 4 measurable cutaneous lesion Treatment cART least 12 month , without wash last 6 month undetectable HIVRNA ( 50 copies/mL ) History treatment failure relapse 1 chemotherapy Progressive disease need new specific therapy Washout 4 week previous specific Kaposi sarcoma chemotherapy ( 8 week Interferon IFN therapy ) Karnofsky performance status 70 % Social security ( State Medical Assistance social security scheme ) Agree abstain donate blood Agree donate semen Agree share study drug another person Childbearing breastfeeding ( positive betaHCG serum ) Kaposi sarcoma visceral location Kaposi sarcoma cardiac and/or bronchopulmonary localisation 2 viral load 50 copies/mL Highly active antiretroviral therapy ( HAART ) , last 6 month Opportunistic infection , uncontrolled infection Cardiac disease Castleman disease lymphoma Other cancer previous current haematological malignancy Polyneuritis , grade 2 Association neurotoxic drug isoniazid , d4T Neutrophil polynuclear count 1000/mm3 platelet 75000/mm3 Life expectation 2 month Creatinine clearance equal 50 mL/min ( CockcroftGault formula ) Serum Glutamopyruvate Transferase ( SGPT ) Serum Glutamooxaloacetate Transferase ( SGOT ) equal 3 Concomitant treatment antineoplastic drug Known allergy hypersensitivity aspirin , lenalidomide Contraindication anticoagulant drug Safeguard justice</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Lenalidomide</keyword>
	<keyword>Kaposi</keyword>
	<keyword>HIV</keyword>
	<keyword>efficacy</keyword>
	<keyword>safety</keyword>
</DOC>